Needham Reiterates Buy on NeoGenomics, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson reiterates a Buy rating on NeoGenomics (NASDAQ:NEO) and maintains a $19 price target.
July 30, 2024 | 10:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson reiterates a Buy rating on NeoGenomics (NASDAQ:NEO) and maintains a $19 price target.
The reiteration of a Buy rating and the maintenance of a $19 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100